Conference call on the report on interim report
Invitation to attend Vitrolife's conference call regarding presentation of the
interim report January - March 2010. The presentation will be held in English.
Time: Tuesday, April 27, 2010 at 3 p.m. CET.
Registration can be done in advance under the following link:
https://eventreg1.conferencing.com/webportal3/reg.html?Acc=830257&Conf=172677
or shortly before time of the conference starts on:
Telephone number: +46 8 505 201 10 (Please quote 864322)
Conference name: Vitrolife
Vitrolife participants:
Magnus Nilsson, CEO
Eva Nilsagård, CFO
The press release for Vitrolife's report on operations will be released at 8.30
a.m. CET on the same day.
Before the conference call, slides will be available at the company web page,
www.vitrolife.com, under the section Investors/News.
A recorded version of the presentation will be available for seven days on
number +46 8 505 203 33, access code 864322.
Gothenburg
April 22, 2010
Magnus Nilsson
CEO
Queries should be addressed to:
Eva Nilsagård, CFO, phone +46 31 721 80 13
________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation.
The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes.
Vitrolife today has approximately 170 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy, United
Kingdom and Japan. Production facilities are housed in Sweden and USA.
The Vitrolife share is listed on NASDAQ OMX Nordic Exchange, Small Cap.
________________________________________________________________________________
________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.
This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Conference call on the report on interim report
| Source: Vitrolife AB
Attachments
